Patents by Inventor Thomas R. Beattie
Thomas R. Beattie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6223691Abstract: The invention is directed to an animal carrier for use inside and outside of vehicles which comprises a cage-like enclosure having a top, a front, a rear, and a pair of sides intersecting with at least the front and a carriage for supporting the enclosure having a bottom, a front, a rear, and a pair of sides intersecting with at least the rear. Attachment members removably connect the cage with the carriage. At least one wedge is secured with the carriage rear and is adapted to be engaged with a seat belt of the vehicle for removably securing the carrier within the vehicle.Type: GrantFiled: August 22, 2000Date of Patent: May 1, 2001Inventor: Thomas R. Beattie
-
Patent number: 5342935Abstract: Hydroxymacrolides and derivatives of the general structural Formula I: ##STR1## have been prepared from suitable precursors by oxidation at C-20. These macrolides are useful as antagonists of FK-506-type immunosuppressants. The compounds of the present invention are useful for modifying dosages of FK-506-type immunosuppressants in the treatment of autoimmune diseases, infectious diseases and/or the prevention of rejection of foreign organ transplants. In addition, the compounds of the present invention have utility as antidotes for overdoses of FK-506-type immunosuppressants.Type: GrantFiled: December 2, 1992Date of Patent: August 30, 1994Assignee: Merck & Co., Inc.Inventors: Thomas R. Beattie, Matthew J. Wyvratt, Francis J. Dumont
-
Patent number: 5273979Abstract: Described is a process for producing a new immunosuppressant, a C-31 desmethyl, C-19/C-22 cyclic hemiketal biotransformation analog (Compound I) of FR-900520, under novel fermentation conditions utilizing the novel microorganism, Streptomyces, lavendulae ATCC No. 55209. Also disclosed is the C-31 methylated derivative (Compound II) of Compound I produced by enzymatic methylation using 31-O-desmethylimmunomycin O-methyl transferase, (DIMT), a methyl transferase enzyme. The macrolide immunosuppressants are useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.Type: GrantFiled: August 1, 1991Date of Patent: December 28, 1993Assignee: Merck & Co., Inc.Inventors: Shieh-Shung T. Chen, Raymond F. White, Georgette Dezeny, Byron H. Arison, Thomas R. Beattie, Amy M. Hale, Francis Dumont
-
Patent number: 5208228Abstract: Aminomacrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by incorporation of a nitrogen substituent at C-3" and/or C-4" of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases and/or the prevention of rejection of foreign organ transplants. In addition, these macrolide immunosuppressants are useful in the topical treatment of inflammatory and hyperproliferative skin diseases and cutaneous manifestations of immunologically-mediated illnesses. Also, these macrolides are useful in the treatment of reversible obstructive airways disease, particularly asthma.Type: GrantFiled: May 13, 1991Date of Patent: May 4, 1993Assignee: Merck & Co., Inc.Inventors: Hyun O. Ok, Thomas R. Beattie, Michael H. Fisher, Matthew J. Wyvratt, Mark Goulet
-
Patent number: 5190950Abstract: A method for the modification of treatment of an immuno regulatory disorder or disease with an FK-506-type immunosuppressive macrolide comprising the administration to a mammalian species in need of such modification of an effective amount of a compound of the formula I.Type: GrantFiled: September 26, 1991Date of Patent: March 2, 1993Assignee: Merck & Co., Inc.Inventors: Thomas R. Beattie, Matthew J. Wyvratt, Francis J. Dumont
-
Patent number: 5189042Abstract: Fluoromacrolides and derivatives of the general structural Formula I: ##STR1## have been prepared from suitable precursors by oxidation and fluorination at C-20. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases and/or the prevention of rejection of foreign organ transplants. In addition, these macrolide immunosuppressants are useful in the topical treatment of inflammatory and hyperproliferative skin diseases and cutaneous manifestations of immunologically-mediated illnesses. Also, these macrolides are useful in the treatment of reversible obstructive airways disease, particularly asthma. Furthermore, these macrolides are useful as hair revitalizing agents, especially in the treatment of male pattern alopecia or alopecia senilis.Type: GrantFiled: August 22, 1991Date of Patent: February 23, 1993Assignee: Merck & Co. Inc.Inventors: Mark Goulet, Thomas R. Beattie, Matthew J. Wyvratt
-
Patent number: 5068323Abstract: Ring-expanded macrolides related to FK-506 have immunosuppressive activity.Type: GrantFiled: April 10, 1990Date of Patent: November 26, 1991Assignee: Merck & Co., Inc.Inventors: Matthew J. Wyvratt, Jr., Thomas R. Beattie, Hyun Ok, Byron H. Arison, Michael H. Fisher
-
Patent number: 5057608Abstract: Ring-expanded, immunosuppressive macrolides, are produced by heating and rearranging FK-506 and related compounds.Type: GrantFiled: April 10, 1990Date of Patent: October 15, 1991Assignee: Merck & Co., Inc.Inventors: Matthew J. Wyvratt, Jr., Thomas R. Beattie, Hyun O. Ok, Byron H. Arison, Michael H. Fisher
-
Patent number: 4595693Abstract: Analogs of 2,5-Diaryl tetrahydrofurans which were substituted or unsubstituted at 3,4-positions were prepared.These compounds are found to have potent and specific PAF (Platelet Activating Factor) antagonistic activities and thereby useful in the treatment of various diseases or disorders mediated by the PAF, for example, inflammation, cardiovascular disorder, asthma, lung edema, adult respiratory distress syndrome, pain, and aggregation of platelets.Type: GrantFiled: June 4, 1984Date of Patent: June 17, 1986Assignee: Merck & Co., Inc.Inventors: Tesfaye Biftu, Thomas W. Doebber, San-Bao Hwang, Thomas R. Beattie, Tsung-Ying Shen, Robert Stevenson
-
Patent number: 4539332Abstract: Analogs of 2,5-Diaryl tetrahydrofurans which were substituted or unsubstituted at 3,4-positions were prepared.These compounds are found to have potent and specific PAF (Platelet Activating Factor) antagonistic activities and thereby useful in the treatment of various diseases or disorders mediated by the PAF, for example, inflammation, cardiovascular disorder, asthma, lung edema, adult respiratory distress syndrome, pain, and aggregation of platelets.Type: GrantFiled: November 14, 1983Date of Patent: September 3, 1985Assignee: Merck & Co., Inc.Inventors: Tesfaye Biftu, San-Bao Hwang, Thomas W. Doebber, Thomas R. Beattie, Tsung-Ying Shen
-
Patent number: 4515722Abstract: Phosphatidyl inositol analogs are found to be effective phospholipase C inhibitors and thereby potent anti-inflammatory and analgesic agents. These phosphatidyl inositol analogs are prepared by condensation of a protected inositol with a substituted phosphonic or phosphorous acid followed by removal of protecting groups.Type: GrantFiled: March 30, 1982Date of Patent: May 7, 1985Assignee: Merck & Co., Inc.Inventors: Shu S. Yang, Thomas R. Beattie, Philippe L. Durette, Timothy F. Gallagher, Tsung-Ying Shen
-
Patent number: 4474806Abstract: Sulfonyl or carbonyl derivatives of inositols are found to be effective phospholipase C inhibitors and thereby potent anti-inflammatory and analgesic agents. These inositol derivatives are prepared by condensation of a protected inositol with a substituted sulfonic or carboxylic acid derivative followed by removal of protecting groups.Type: GrantFiled: May 10, 1982Date of Patent: October 2, 1984Assignee: Merck & Co., Inc.Inventors: Thomas R. Beattie, Shu S. Yang
-
Patent number: 4390693Abstract: Novel cephalosporin compounds having a substituted or unsubstituted vinyl group at the 3-position are prepared by the reaction of a phosphoranylidene compound with a compound containing a carbonyl group. The novel cephalosporin compounds are active against a range of gram-negative and gram-positive microorganisms and are of value in human and veterinary medicine.Type: GrantFiled: October 9, 1980Date of Patent: June 28, 1983Assignee: Merck & Co., Inc.Inventors: Thomas R. Beattie, John Hannah, David B. R. Johnston
-
Patent number: 4296111Abstract: Disclosed are antibiotic 7-(substituted methyl) cephalosporins, derivatives and nuclear analogues thereof; wherein the methyl substituent is, inter alia, hydroxyl, ketonic oxygen, imino nitrogen, amino or thio. Also disclosed are processes for the preparation of such compounds and their pharmaceutically acceptable salt, ester and amide derivatives; pharmaceutical compositions comprising such compounds; and methods of treatment comprising administering such compounds and compositions when an antibiotic effect is indicated.Type: GrantFiled: June 14, 1979Date of Patent: October 20, 1981Assignee: Merck & Co. Inc.Inventors: Thomas R. Beattie, Burton G. Christensen, Frank P. Dininno
-
Patent number: 4255423Abstract: Novel cephalosporin compounds having a substituted or unsubstituted vinyl group at the 3-position are prepared by the reaction of a phosphoranylidene compound with a compound containing a carbonyl group. The novel cephalosporin compounds are active against a range of gram-negative and gram-positive microorganisms and are of value in human and veterinary medicine.Type: GrantFiled: July 27, 1977Date of Patent: March 10, 1981Assignee: Merck & Co., Inc.Inventors: Thomas R. Beattie, John Hannah, David B. R. Johnston
-
Patent number: 4207323Abstract: Disclosed are antibiotic 6-(substituted methyl) penicillins, derivatives and nuclear analogues thereof; wherein the methyl substituent is, inter alia, hydroxyl, ketonic oxygen, imino nitrogen, amino or thio. Also disclosed are processes for the preparation of such compounds and their pharmaceutically acceptable salt, ester and amide derivatives; pharmaceutical compositions comprising such compounds; and methods of treatment comprising administering such compounds and compositions when an antibiotic effect is indicated.Type: GrantFiled: May 1, 1978Date of Patent: June 10, 1980Assignee: Merck & Co., Inc.Inventors: Thomas R. Beattie, Frank P. Dininno, Burton G. Christensen
-
Patent number: 4156693Abstract: Novel linear, unbranched, non-cross-linked polymers particularly poly-[{methyl-(3-trimethylammoniopropyl)iminio}trimethylene dihalide] are prepared by the polymerization of the novel monomer, 3-[N'-(3-halopropyl)-N'-methylamino]-N,N,N-trimethyl-1-propanaminium halide, or an acid addition salt thereof preferably in an oxygen excluded environment, e.g., under nitrogen or argon. The polymer, especially after modification of terminal groups, is an excellent oral anticholesterolemic.Type: GrantFiled: April 1, 1977Date of Patent: May 29, 1979Assignee: Merck & Co., Inc.Inventor: Thomas R. Beattie
-
Patent number: 4150156Abstract: Disclosed are antibiotic 3-(substituted thio)-7-(substituted methyl) cephalosporins, derivatives and analogues thereof; wherein the methyl substituent is, inter alia, hydroxyl, ketonic oxygen, imino nitrogen, amino or mercapto. Also disclosed are processes for the preparation of such compounds and their pharmaceutically acceptable salt, ester and amide derivatives; pharmaceutical compositions comprising such compounds; and methods of treatment comprising administering such compounds and compositions when an antibiotic effect is indicated.Type: GrantFiled: May 8, 1978Date of Patent: April 17, 1979Assignee: Merck & Co., Inc.Inventors: Thomas R. Beattie, Lovji D. Cama, Burton G. Christensen, Frank P. Dininno
-
Patent number: 4064344Abstract: Novel 7-methoxy 3-phosphoranylidene cephem compounds which find utility as intermediates in the preparation of antibiotically active 7-methoxy-3-vinyl cephalosporins.Type: GrantFiled: April 14, 1976Date of Patent: December 20, 1977Assignee: Merck & Co., Inc.Inventors: Thomas R. Beattie, Burton G. Christensen
-
Patent number: 3974151Abstract: Novel 7-methoxy 3-phosphoranylidene cephem compounds which find utility as intermediates in the preparation of antibiotically active 7-methoxy-3-vinyl cephalosporins.Type: GrantFiled: June 5, 1973Date of Patent: August 10, 1976Assignee: Merck & Co., Inc.Inventors: Thomas R. Beattie, Burton G. Christensen